EUVIMEDEUVIMED entdecken
Crossref

Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic α v β 6 Integrin Inhibitors

Panayiotis A Procopiou iD, John Barrett, Matthew H J Crawford, Richard J D Hatley iD, Ashley P Hancock, John M Pritchard, James E Rowedder, Royston C B Copley, Robert J Slack, Steven L Sollis, Lee R Thorp, Rhys A Lippa und 2 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Panayiotis A Procopiou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Science & Technology, Medicine Design, Stevenage SG1 2NY, United Kingdom. Hauptthemen laut MEDLINE: Integrins, Biological Availability, Antigens, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of 3-aryl((S)-3-fluoropyrrolidin-1-yl)butanoic acids were developed as potent orally bioavailable αvβ6 integrin inhibitors. Starting from a zwitterionic peptidomimetic series optimized for inhaled administration, the balancing of potency and passive permeability to achieve suitable oral agents through modification and exploration of aryl substituents and pKa of the central cyclic amine is described. (S)-4-((S)-3-Fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl)butanoic acid was found to have highly desirable oral pharmacokinetic profiles in rat, dog, and minipig, with low to moderate clearance (26%, 7%, and 18% liver blood flow, respectively), moderate volumes of distribution (3.6, 1.4, and 0.9 L/kg, respectively), high to complete oral bioavailabilities, high αvβ6 integrin potency of pIC50 of 8.0, and high solubility in physiological media (>2 mg/mL). Equating to the estimated human dose range of 10-75 mg b.i.d. to achieve 90% αvβ6 target engagement at Cmin, it was selected for further investigation as a potential therapeutic agent for the treatment of idiopathic pulmonary fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IntegrinsBiological AvailabilityAntigens, NeoplasmAnimalsDogsRatsAdministration, OralHumansSwineStructure-Activity RelationshipDrug DiscoverySwine, MiniatureMaleRats, Sprague-Dawley

Substanzen

integrin alphavbeta6IntegrinsAntigens, Neoplasm

Autor:innen und Institutionen

  • Medicinal Science & Technology, Medicine Design, Stevenage SG1 2NY, United Kingdom.
  • Discovery Drug Metabolism & Pharmacokinetics, In Vitro In Vivo Translation, Stevenage SG1 2NY, United Kingdom.
  • Translational Biology, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom.
  • Medicine Development & Supply, Drug Substance Development, Materials Science, Stevenage SG1 2NY, United Kingdom.

ORCID-Profile: Panayiotis A Procopiou, Richard J D Hatley, Simon J F Macdonald, Tim N Barrett

Zitieren

APA

Procopiou, P. A., Barrett, J., Crawford, M. H. J., Hatley, R. J. D., Hancock, A. P., Pritchard, J. M., Rowedder, J. E., Copley, R. C. B., Slack, R. J., Sollis, S. L., Thorp, L. R., Lippa, R. A., Macdonald, S. J. F., & Barrett, T. N. (2024). Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic α v β 6 Integrin Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01430

Vancouver

Procopiou PA, Barrett J, Crawford MHJ, Hatley RJD, Hancock AP, Pritchard JM, et al. Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic α v β 6 Integrin Inhibitors. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01430

BibTeX
@article{Procopiou2024,
  author = {Procopiou, Panayiotis A and Barrett, John and Crawford, Matthew H J and Hatley, Richard J D and Hancock, Ashley P and Pritchard, John M and Rowedder, James E and Copley, Royston C B and Slack, Robert J and Sollis, Steven L and Thorp, Lee R and Lippa, Rhys A and Macdonald, Simon J F and Barrett, Tim N},
  title = {Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic α v β 6 Integrin Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01430}
}
Kostenlos starten →